AlphaRx To Present at 47th Annual ICAAC

Tuesday, September 18, 2007 General News J E 4
MARKHAM, ON, Sept. 17 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX), a specialty pharmaceutical company dedicated to developing the nextgeneration of therapeutic products using nanotechnology, today announced thatits Antituberculosis product candidate, Streptomycin nanoparticles, will bethe subject of a slide presentation under the title "Advances in Treatment andPathogenesis of Mycobacterial Infections" at the 47th Annual InterscienceConference on Antimicrobial Agents and Chemotherapy (ICAAC) to be heldSeptember 17-20, 2007 in Chicago. More than 12,000 physicians, researchers andother healthcare professionals from around the globe gather each year at ICAACto foster worldwide solutions to the problem of infectious diseases.

Dr. Joseph Schwarz, Chief Scientist of AlphaRx is scheduled to present"Effective Treatment of Tuberculosis in Mice with NanoparticulatedStreptomycin." The presentation will elucidate that Streptomycin in theCompany's nanoparticulated delivery platform, demonstrated increased efficacyand is effectively a cure of model tuberculosis at a dosage 80% lower thanthat of free drug, provided 100% survival in experimental TB mice model andexhibited noticeable sustained release and targeting of the incorporated drug.

For more information on AlphaRx visit, For moreinformation on the ICAAC 47th annual meeting, scheduled for September 17-20,2007, visit

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietarysite-specific nanoparticulate drug delivery systems to develop novelformulations of drugs that are insoluble or poorly soluble in water or haveyet to be administrable to the human body with an acceptable delivery method.The Company also discovers and develops novel, small-molecule drugs for thetreatment of inflammatory diseases and neurodegenerative diseases.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning andpursuant to the Safe Harbor provisions of the Securities Litigation Reform Actof 1995 and involve risks and uncertainties that may individually or mutuallyimpact the matters herein described, including but not limited to productdevelopment and acceptance, manufacturing, competition, regulatory and/orother factors, which are outside the control of the companies.

SOURCE AlphaRx Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
SXC Health Solutions announces two new board membe...
North Castle Partners Invests in Atkins Nutritiona...